An optimized prediction framework to assess the functional impact of pharmacogenetic variants

Prediction of phenotypic consequences of mutations constitutes an important aspect of precision medicine. Current computational tools mostly rely on evolutionary conservation and have been calibrated on variants associated with disease, which poses conceptual problems for assessment of variants in poorly conserved pharmacogenes. Here, we evaluated the performance of 18 current functionality prediction methods leveraging experimental high-quality activity data from 337 variants in genes involved in drug metabolism and transport and found that these models only achieved probabilities of 0.1–50.6% to make informed conclusions. We therefore developed a functionality prediction framework optimized for pharmacogenetic assessments that significantly outperformed current algorithms. Our model achieved 93% for both sensitivity and specificity for both loss-of-function and functionally neutral variants, and we confirmed its superior performance using cross validation analyses. This novel model holds promise to improve the translation of personal genetic information into biological conclusions and pharmacogenetic recommendations, thereby facilitating the implementation of Next-Generation Sequencing data into clinical diagnostics.

[1]  H. Carter,et al.  Identifying Mendelian disease genes with the Variant Effect Scoring Tool , 2013, BMC Genomics.

[2]  C. Sander,et al.  Predicting the functional impact of protein mutations: application to cancer genomics , 2011, Nucleic acids research.

[3]  Masamitsu Maekawa,et al.  Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation. , 2015, Drug metabolism and pharmacokinetics.

[4]  Charles Swanton,et al.  Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine , 2014, Genome Biology.

[5]  B. Fernandez,et al.  Utility of whole‐exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care , 2015, Clinical genetics.

[6]  M. Ingelman-Sundberg,et al.  Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response , 2016, Genetics in Medicine.

[7]  M. Hiratsuka,et al.  Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity. , 2014, Drug metabolism and pharmacokinetics.

[8]  Nidhi Mathur,et al.  Computational approaches for predicting mutant protein stability , 2016, Journal of Computer-Aided Molecular Design.

[9]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[10]  Thomas A. Peterson,et al.  Towards precision medicine: advances in computational approaches for the analysis of human variants. , 2013, Journal of molecular biology.

[11]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[12]  Patrick F Sullivan,et al.  The genomics of schizophrenia: update and implications. , 2013, The Journal of clinical investigation.

[13]  Masahiro Hiratsuka,et al.  Functional Characterization of 17 CYP2D6 Allelic Variants (CYP2D6.2, 10, 14A–B, 18, 27, 36, 39, 47–51, 53–55, and 57) , 2008, Drug Metabolism and Disposition.

[14]  Xiaohui Xie,et al.  Identifying novel constrained elements by exploiting biased substitution patterns , 2009, Bioinform..

[15]  Justin C. Fay,et al.  Identification of deleterious mutations within three human genomes. , 2009, Genome research.

[16]  J. Reis-Filho,et al.  Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations , 2014, Genome Biology.

[17]  K. Pollard,et al.  Detection of nonneutral substitution rates on mammalian phylogenies. , 2010, Genome research.

[18]  David M. W. Powers,et al.  Evaluation: from precision, recall and F-measure to ROC, informedness, markedness and correlation , 2011, ArXiv.

[19]  Daniel J. Park,et al.  Variant effect prediction tools assessed using independent, functional assay-based datasets: implications for discovery and diagnostics , 2017, Human Genomics.

[20]  D. Haussler,et al.  Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. , 2005, Genome research.

[21]  Melissa A. Basford,et al.  Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network , 2016, Clinical pharmacology and therapeutics.

[22]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[23]  Andrea Gaedigk,et al.  CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. , 2003, Clinical chemistry.

[24]  Claudio J. Verzilli,et al.  An Abundance of Rare Functional Variants in 202 Drug Target Genes Sequenced in 14,002 People , 2012, Science.

[25]  R. Gibbs,et al.  Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. , 2015, Human molecular genetics.

[26]  Bartha Maria Knoppers,et al.  Population genetic testing for cancer susceptibility: founder mutations to genomes , 2016, Nature Reviews Clinical Oncology.

[27]  B. Taylor,et al.  Implementing Genome-Driven Oncology , 2017, Cell.

[28]  J. Miller,et al.  Predicting the Functional Effect of Amino Acid Substitutions and Indels , 2012, PloS one.

[29]  S. Henikoff,et al.  Predicting the effects of amino acid substitutions on protein function. , 2006, Annual review of genomics and human genetics.

[30]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.

[31]  Masamitsu Maekawa,et al.  Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities , 2017, Drug Metabolism and Disposition.

[32]  Hua Xu,et al.  A comparative study of disease genes and drug targets in the human protein interactome , 2015, BMC Bioinformatics.

[33]  Kenneth Offit,et al.  Genome-wide association studies of cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Mark I McCarthy,et al.  Genomics, type 2 diabetes, and obesity. , 2010, The New England journal of medicine.

[35]  Tom R. Gaunt,et al.  Predicting the Functional, Molecular, and Phenotypic Consequences of Amino Acid Substitutions using Hidden Markov Models , 2012, Human mutation.

[36]  Colin Campbell,et al.  An integrative approach to predicting the functional effects of non-coding and coding sequence variation , 2015, Bioinform..

[37]  O. Lichtarge,et al.  Predicting phenotype from genotype: Improving accuracy through more robust experimental and computational modeling , 2017, Human mutation.

[38]  Xiaohui Xie,et al.  DANN: a deep learning approach for annotating the pathogenicity of genetic variants , 2015, Bioinform..

[39]  Anthony J. Kusalik,et al.  Computational prediction of eukaryotic phosphorylation sites , 2011, Bioinform..

[40]  M. Vihinen,et al.  Performance of mutation pathogenicity prediction methods on missense variants , 2011, Human mutation.

[41]  S. Henikoff,et al.  Predicting deleterious amino acid substitutions. , 2001, Genome research.

[42]  M. Ingelman-Sundberg,et al.  Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects , 2012, The Pharmacogenomics Journal.

[43]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[44]  M. Ingelman-Sundberg,et al.  Genetic variation in the human cytochrome P450 supergene family , 2015, Pharmacogenetics and genomics.

[45]  Jeffrey P. Jones,et al.  An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. , 2002, Biochemical and biophysical research communications.

[46]  Trevor Hastie,et al.  REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. , 2016, American journal of human genetics.

[47]  M. Ingelman-Sundberg,et al.  Precision Medicine and Rare Genetic Variants. , 2016, Trends in pharmacological sciences.

[48]  L. Milani,et al.  Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments , 2017, The AAPS Journal.

[49]  K. Boycott,et al.  Rare-disease genetics in the era of next-generation sequencing: discovery to translation , 2013, Nature Reviews Genetics.

[50]  Serafim Batzoglou,et al.  Identifying a High Fraction of the Human Genome to be under Selective Constraint Using GERP++ , 2010, PLoS Comput. Biol..